99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2014

Primary Completion Date

October 17, 2017

Study Completion Date

October 17, 2017

Conditions

Rheumatoid ArthritisAnkylosing Spondylitis

Interventions

DRUG

99mTc-rhAnnexin V-128

1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.

Trial Locations (1)

Centre Hospitalier Universitaire Vaudois, Lausanne